HH Ting

HH Ting has a long and varied work experience. In 2010, they became the Chairman and co-founder of Biovue Technology Ltd. In 2012, they became the CEO and co-founder of Oxford Vacmedix. In 2016, they were a Management Consultant and Head of Nuclear Medicine at CGN Nuclear Technology and also a Co-founder and Executive Director at NanoMab Technology Ltd. In 2021, they joined Radiopharm Theranostics as a member of the Scientific Advisory Board. Finally, in 2022, they became a Co-founder and Chief Strategy Officer at Full-Life Technologies and a Non Executive Director at NanoMab Technology.

HH Ting attended the University of Oxford from 1979 to 1982, where they earned a D.Phil in the Faculty of Medicine.